Back to News
Market Impact: 0.15

Guru Fundamental Report for TMO

TMONDAQ
Company FundamentalsAnalyst InsightsInvestor Sentiment & PositioningHealthcare & BiotechCapital Returns (Dividends / Buybacks)Market Technicals & Flows
Guru Fundamental Report for TMO

Validea's report indicates Thermo Fisher Scientific (TMO) rates highest under the Pim van Vliet Multi-Factor Investor model, a quantitative strategy seeking low volatility, strong momentum, and high net payout yields. However, TMO's 50% rating falls short of the 80% threshold for investor interest, as neutral momentum and net payout yield metrics, despite passing market cap and low volatility criteria, resulted in a 'FAIL' on the final rank for this specific strategy.

Analysis

Thermo Fisher Scientific (TMO) has been evaluated by Validea using the Pim van Vliet Multi-Factor Investor model, a quantitative strategy designed to identify low-volatility stocks that also exhibit strong momentum and high net payout yields. As a large-cap stock in the Medical Equipment & Supplies industry, TMO successfully meets the model's criteria for market capitalization and low standard deviation, indicating favorable low-risk characteristics. However, the analysis reveals significant weaknesses in other key areas, with the company receiving a 'NEUTRAL' rating on both its 'Twelve Minus One Momentum' and 'Net Payout Yield'. These shortcomings resulted in an overall model score of 50%, which is substantially below the 80% threshold required to signal interest from this specific strategy, leading to a final rank of 'FAIL'. The moderately negative sentiment score of -0.5 reflects this failure to qualify, suggesting that despite its low volatility, TMO is not an attractive candidate under this conservative, factor-based framework.

AllMind AI Terminal

AI-powered research, real-time alerts, and portfolio analytics for institutional investors.

Request a Demo